Regenerative medical group Collagen Solutions saw shares fall 14 per cent yesterday after it indicated that full-year revenue growth will fall short of market expectations.

Collagen, which makes medical-grade components at a facility in Glasgow, widened losses in the six months to September 30 to £1.4 million on revenue which slipped six per cent to £1.7m.

The group said the reduction in revenue forecasts came as a result of delays to medical device projects with clients, caused by either internal funding issues or external issues such as regulatory hold ups.

There group also announced it would be applying for CE Marking for its ChondroMimetic product early next year.